Submissions from 2024
51125 PATIENT EXIT INTERVIEWS ILLUSTRATE BENEFIT OF TRIFAROTENE ON ACNE-INDUCED PIGMENTARY PROBLEMS, Andrew Alexis, James Del Rosso, Seth Forman, Antonio Calatayud, John Browning, Vivian Laquer, J. P. York, Rajeev Chavda, Sunil Dhawan, Angela Moore, and Linda Stein-Gold
53113 Trifarotene shown to improve acne and related sequelae (scars, pigmentation), Andrew Alexis, Stephen Schleicher, Jonathan Weiss, Valerie Callender, J. P. York, Rajeev Chavda, Fran E. Cook Bolden, Neal Bhatia, James Del Rosso, and Linda Stein-Gold
53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types, Andrew Alexis, Linda Stein-Gold, Rajeev Chavda, J. P. York, James Del Rosso, and Jonathan Weiss
54147 Efficacy of Ruxolitinib Cream for Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Baseline Clinical Characteristics: Subgroup Analysis From a Randomized Phase 3 Study>(TRuE-AD3), April W. Armstrong, Lawrence F. Eichenfield, Lara W. Lee, Kanwaljit K. Brar, Joel C. Joyce, Seth B. Forman, Weily Soong, Howard Sofen, Brett Angel, Qian Li, and Linda Stein-Gold
Dermatology personal statement themes and match outcomes, Redina Bardhi, L. Bugosh, M. Al-Hadidi, J. Duong, S. Colbert, B. Jones, and S. Daveluy
54396 Ultrasound Mapping for Carbon Dioxide Surgery in Hidradenitis Suppurativa, Redina Bardhi, Mohsen Mokhtari, Mavra Masood, Iltefat Hamzavi, and Indermeet Kohli
52726 Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II, Falk G. Bechara, Christopher Sayed, Stephanie Goldberg, Jacek C. Szepietowski, Philippe Guillem, Iltefat Hamzavi, Pratiksha Dokhe, Paulatsya Joshi, Robert Rolleri, Leah Davis, and Hessel H. van der Zee
53894 Roflumilast foam 0.3% once daily in patients with seborrheic dermatitis: Improvement in patient reported outcomes and pruritus from a phase 3 trial (STRATUM), Neal Bhatia, Fran Cook-Bolden, Janet DuBois, Laura Ferris, Linda Stein-Gold, Irina Turchin, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, and David H. Chu
Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial, Robert Bissonnette, Mark S. Lee, Seth B. Forman, Linda F. Stein Gold, Howard Kallender, Brett Angel, Yutzu Kuo, and Amy S. Paller
Tapinarof cream 1% once daily: Interim analysis of ADORING 3 phase 3 long-term extension trial in adults and children down to age 2 years with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
53928 Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis, Robert Bissonnette, Linda Stein-Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis, Christopher G. Bunick, Neal Bhatia, James Del Rosso, Zoe D. Draelos, Lawrence F. Eichenfield, Leon H. Kircik, Mark G. Lebwohl, Melinda Gooderham, Lawrence J. Green, Adelaide A. Hebert, Ronald B. Vender, Matthew Zirwas, Eric L. Simpson, Linda F. Stein Gold, Melissa Seal, Scott Snyder, David W. Osborne, Patrick Burnett, Robert C. Higham, David H. Chu, and David R. Berk
50584 Online Continuing Medical Education Improved Dermatologists’ Knowledge, Competence, and Confidence About New Topical Treatments for Psoriasis, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
54214 Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Previous Medication History: Subgroup Analysis From the>Randomized, Phase 3 TRuE-AD3 Study, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
Global survey reveals demand for additional photoprotection education in Australia...Cancer Nurses Society of Australia (CNSA) 26th Annual Congress, June 19-21, 2024, Brisbane, Queensland, L. Dousset, K. Khosrotehrani, P. Guitera, T. Passeron, B. Dreno, Henry W. Lim, D. Kerob, and J. Krutmann
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study, Lawrence F. Eichenfield, April W. Armstrong, Linda F. Stein Gold, Andrea L. Zaenglein, Lara Wine Lee, Kanwaljit K. Brar, Joel C. Joyce, Kristen E. Holland, Brett Angel, Daniel Sturm, Qian Li, and Eric L. Simpson
51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo, Khaled Ezzedine, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Iltefat Hamzavi
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study, Melinda J. Gooderham, Stephan Weidinger, Eric L. Simpson, Mette Deleuran, Linda F. Stein Gold, Saleem A. Farooqui, Pinaki Biswas, Gary Chan, Erman Güler, and Herwig Koppensteiner
53495 Disparity of cost and protective features between tinted and non-tinted sunscreens, Judy Hamad, Christopher Chung, Henry W. Lim, and Natalie H. Matthews
PCR163 Treatment Priorities and Unmet Need Among Adults and Adolescents With Non-Segmental Vitiligo in the United States, Iltefat Hamzavi, J. Coulter, A. Balaji, L. Franco, S. Darnell, E. Law, S. Kurosky, R. Adiri, N. Elbuluk, and B. Hauber
51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo, Iltefat Hamzavi, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Khaled Ezzedine
54585 Vitiligo, Nutrition and the Gut Microbiome: A Narrative Review, Marlee Hewitt, Karan Pandher, Nada Elbuluk, and Richard Huggins
Environment impacts the phenotypic severity of flaky tail, MC903-induced inflammation, and dysbiosis in filaggrin-null mice, Autumn Hicks, Mohammed H. M Bharmal, A. Schmidt, Q Zheng, Congcong Yin, Peter Dimitrion, Qing-Shing Mi, Emelia Grice, Indra Adrianto, and Cristina de Guzman Strong
54843 QR Codes and Dermatology: Examining Resident Attitudes on Digitized After Visit Summaries, Mustufa Jafry, Joseph Fakhoury, and Holly Kerr
54853 Trends in Incidence and Mortality of Pleomorphic Dermal Sarcoma: A Retrospective Cohort Study Using SEER Data, Mustufa Jafry and Molly Powers
54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey, Delphine Kerob, Thierry Passeron, Andrew Alexis, Brigitte Dreno, Liu Wei, Akimichi Morita, Chee Leok, Susana Puig, Sergio Schalka, and Henry W. Lim
54542 Assessing the risk of subcutaneous nodules, Rachel Krevh, Redina Bardhi, Karan Pandher, Gordon Jacobsen, and Laurie Kohen
53329 Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators, Olivia Lamberg, Karan Pandher, and Henry Lim
51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Maria Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
51675 Safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement: changes in PPASI and PASI from Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
52818 Easy on the Hands: Utilization of a Foot Pedal for Tumescent Anesthesia Delivery, Mavra Masood, Joseph Fakhoury, Angela Parks-Miller, and Iltefat Hamzavi
52910 Projected burden of melanoma clinical surveillance in the United States, Natalie Matthews, Judy Hamad, James Henderson, Angela Mariotto, Martin Weinstock, and Charles Ellis
50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis, Amy McMichael, Linda Stein-Gold, Jennifer Soung, Chesahna Kindred, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Candrice R. Heath, Tina Bhutani, Maxwell Sauder, and Andrew Alexis
54078 Examining Hair Preservation in Manual vs. Machine Scalp Cooling by Chemotherapy Regimen: A Meta-Analysis, Abena Minta, Sarah Shareef, Patrick Schnell, Trevor Nessel, Lucy Rose, Brittany Dulmage, and Taylor Novice
52736 Assessment of Color Match of Universal Tinted Sunscreens in Fitzpatrick Skin Phototypes I-VI, Mohsen Mokhtari, Redina Bardhi, Mavra Masood, Deena Abdel-Gadir, Dorothea McGowan, Brittany N. Lane, Marissa Ceresnie, Henry Lim, Iltefat Hamzavi, Indermeet Kohli, and Tasneem Mohammad
52503 The financial burden of scalp cooling therapy: a non-profit organization data analysis, Madison Novice, Taylor Novice, Molly Powers, and Kristen L. Sicco
52509 Expanding access to scalp cooling therapy: a review of post-capping satisfaction in patients who received financial assistance from a non-profit organization, Madison Novice, Lucy Rose, Taylor Novice, Allison Darland, Brittany Dulmage, Molly Powers, and Kristen L. Sicco
54337 Full-body Multifocal Pyoderma Gangrenosum in the setting of PASH Syndrome, Sandra Oska, Sasank Konda, and Natalie Matthews
Transforming Growth Factor β-activated Kinase 1 Controls Langerhans Cell Homeostasis through Autophagic Machinery, Nirmal Parajuli, Q. Wang, Q. Yu, James Ge, Qing-Shing Mi, and Li Zhou
Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo, Thierry Passeron, Khaled Ezzedine, Iltefat H. Hamzavi, Nanja van Geel, Bethanee J. Schlosser, Xiaofei Hu, Xiaohong Huang, David Rosmarin, John E. Harris, Heidi S. Camp, and Amit G. Pandya
50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study, Andreas Pinter, Linda Stein-Gold, Jerry Bagel, Stephen K. Tyring, Ronald Vender, Adam Reich, Lev Pavlovsky, Mark I. Kaldas, Tianshuang Wu, Manish Patel, and Kim A. Papp
Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies, Vimal H. Prajapati, Christopher G. Bunick, Kilian Eyerich, Linda F. Stein Gold, Fabrizio Galimberti, Brian Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Cristina Sancho, Ayman Grada, and Alan D. Irvine
50524 Facebook groups provide support and product recommendations for patients using scalp cooling to prevent chemotherapy-induced alopecia: A survey study, Lucy Rose, Madison Novice, Abena Minta, Taylor Novice, and Brittany Dulmage
51716 Hydroquinone and Alternative Agents for Hyperpigmentation: A Systematic Review, Kavya Shivaram, Katherine Edwards, and Tasneem Mohammad
53146 Expert evidence regarding cosmetic procedures in minors, Victoria Shi, Umer Nadir, Misha Haq, Eric Koza, Areeba Ahmed, Melissa Ma, David Ozog, Kristen Kelly, Andrew Krakowski, and Murad Alam
Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up), Jonathan I. Silverberg, Christopher Bunick, H. Chih-ho Hong, Pedro Mendes-Bastos, Linda F. Stein Gold, Antonio Costanzo, Nadia Ibrahim, Cristina Sancho, Xiaoqiang Wu, Yu Han, Gweneth Levy, Kathy Altman, and Kilian Eyerich
Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age, Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda F. Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna M. Tallman, and Leon Kircik
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results, Jonathan I. Silverberg, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, Chia-Yu Chu, H. Chih-ho Hong, Linda F. Stein Gold, Thomas Bieber, Kenji Kabashima, David Rosmarin, Amy Gamelli, Brian Calimlim, Namita Vigna, Xiaofei Hu, Yang Yang, Xiaoqiang Wu, Xiaohong Huang, Smitha Suravaram, Henrique D. Teixeira, Eliza Raymundo, and Alan D. Irvine
A novel efficacy index for long-term therapy outcomes expressed by maintenance of EASI 75 and IGA 0,1 response in atopic dermatitis, Jonathan I. Silverberg, Alan Irvine, Peter Foley, James Del Rosso, Alexander Schacht, Martin Dossenbach, Marta Casillas, Erin Johansson, Gaia Gallo, and Linda F. Stein Gold
Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data, Jonathan I. Silverberg, Linda F. Stein Gold, Diamant Thaçi, Andrew E. Pink, Kim A. Papp, Franz J. Legat, Vivian T. Laquer, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, and Christophe Piketty
Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry, Eric Simpson, Christian Fenske, Alvin Li, Zach Dawson, Yolanda Muñoz Maldonado, Kaylee Ho, Kayla Callahan, Linda F. Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, and Jonathan I. Silverberg
50377 Factors associated with the initiation of a new systemic therapy among adults with atopic dermatitis: Data from the CorEvitas Atopic Dermatitis Registry, Eric Simpson, Alvin Li, Zach Dawson, Kaylee Ho, Linda Stein-Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, and Jonathan Silverberg
Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis, Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda F. Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, and Lawrence F. Eichenfield
52792 Lebrikizumab provides stable skin response with no or minimal fluctuations for up to two years in patients with atopic dermatitis, Jonathan Sliverberg, Andreas Wollenberg, Peter Lio, Jose M. Carrascosa, Marta Casillas, Gaia Gallo, Yuxin D. Fan, Emily Yang, Christian Vestergaard, Linda Stein-Gold, and James Del Rosso
Identifying disparities in phototherapy dosing and research participation among patients with psoriasis by race, ethnicity, and skin phototype: Findings from the light treatment effectiveness study, W. B. Song, B. Bishop, R. Fitzsimmons, A. Bridges, U. Nehal, D. Shin, Henry W. Lim, J. Takeshita, L. Howard, K. Duffin, and J. Gelfand
51480 Efficacy of apremilast in adults with mild-to-moderate plaque psoriasis with scalp involvement: Pooled data from PROMINENT, ADVANCE, and EMBRACE trials, Linda Stein-Gold, Matthias Augustin, Howard Sofen, Paolo Gisondi, Shauna Jardon, Jyotsna Reddy, Henry Zou, and Kristina Callis Duffin
51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials, Linda Stein-Gold, Subhashis Banerjee, Matthew J. Colombo, Renata M. Kisa, Victoria Berger, Kim Hoyt, Jennifer Soung, Tiago Torres, Neal Bhatia, Brad P. Glick, and Mark D. Kaufmann
53949 Tapinarof Cream 1% Once Daily was Well Tolerated for the Treatment of Adults and Children Down to 2 Years of Age with Moderate to Severe Atopic Dermatitis Across Two Pivotal Phase 3 Trials, Linda Stein-Gold, James Del Rosso, Benjamin D. Ehst, Matthew J. Zirwas, Lawrence J. Green, Philip M. Brown, Anna M. Tallman, David S. Rubenstein, and Stephen C. Piscitelli
Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY, Linda F. Stein Gold, Stephan Weidinger, Delphine Staumont-Salle, Saeko Nakajima, Eric L. Simpson, Marjolein de Bruin Weller, Sonya Davey, Kassim Rahawi, and Charlotte Bernigaud
53779 Fixed-Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotions for Plaque Psoriasis on Lower Extremities With Body Hair, Linda Stein-Gold, Edward Lain, George Han, and Abby Jacobson
50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis, Linda Stein-Gold, Marie L. Schuttelaar, Vimal H. Prajapati, Bernhard Homey, Lindsay Strowd, Martin Dossenbach, Chunyuan Liu, Jinglin Zhong, Evangeline Pierce, Helena Agell, and Juan F. Silvestre
53803 Early and Sustained Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Participants with Moderate-to-Severe Scaling or Plaque Elevation, Linda Stein-Gold, Emil Tanghetti, Edward Lain, Andrea Murina, and Abby Jacobson
52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials, Linda Stein-Gold, Diamant Thaci, Norito Katoh, Vivian Shi, Alan Irvine, Maria L. Buziqui Piruzeli, Sonia Montmayeur, Gaia Gallo, and Marjolein de Bruin-Weller
50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study, Linda Stein-Gold, Stephen K. Tyring, H. Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Tianshuang Wu, Vassilis Stakias, Sven Richter, and Kim A. Papp
54203 VISIBLE: Clearance and Symptom Improvement With Guselkumab at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis, Linda Stein-Gold, Jensen Yeung, Adrian O. Rodriguez, Jessica Vasquez, Olivia Choi, Katelyn Rowland, Theodore Alkousakis, Jenny Jeyarajah, Javier Alonso-Llamazares, Stephen Tyring, and April W. Armstrong
REAL WORLD EFFECTIVENESS OF INITIATING TOPICAL THERAPY COMPARED WITH INITIATING APREMILAST EARLY OR LATE, Bruce Strober, Linda F. Stein Gold, Paolo Gisondi, Kate Orroth, Myriam Cordey, Shia T. Kent, Cynthia Deignan, Shauna Jardon, Rohini K. Hernandez, M. Alan Brookhart, and April Armstrong
DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS, B. Strober, H. Sofen, S. Imafuku, C. Paul, M. Gooderham, L. Spelman, S. J. Seo, T. Passeron, R. M. Kisa, V. Berger, E. Vritzali, K. Hoyt, M. J. Colombo, S. Banerjee, M. Augustin, Linda F. Stein Gold, A. Alexis, D. Thaçi, A. Blauvelt, and M. Lebwohl
Spitz-Type Proliferative Nodule With Novel LMNA-RAF1 Fusion Arising Within a Large Congenital Melanocytic Nevus, Gautham Vellaichamy and Ben Friedman
CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa, Ping Wang, Peter Dimitrion, Albert Young, Congcong Yin, Iltefat H. Hamzavi, Indra Adrianto, Li Zhou, and Qing-Shing Mi
52417 Efficacy of the Minority Outreach for High School Students (MOHSS) Program in Addressing Racial and Ethnic Disparities in Skin Cancer Awareness and Outcomes, Kirk Williams, Nikita Wong, Zeynoire Anderson, Starling Tolliver, and Darius Mehregan
Response to ritlecitinib with or without narrow band ultraviolet B (nbUVB) add-on therapy in patients with active non-segmental vitiligo (NSV), Yuji Yamaguchi, Elena Peeva, Roni Adiri, Pranab Ghosh, Lynne Napatalung, Iltefat H. Hamzavi, Amit G. Pandya, Ronald N. Shore, Khaled Ezzedine, and Emma Guttman-Yassky
53351 Predictors of drug survival in patients with hidradenitis suppurativa treated with TNF-alpha-inhibitors, Albert Young, Kathy Lu, Andrea Dai, Dheeraj Kagithala, Eglal Samir, Mark Gregory, Madison Romanski, Peter Dimitrion, Iltefat Hamzavi, and Qing-Sheng Mi
54091 Biologic efficacy and reasons for discontinuation in a tertiary referral hidradenitis suppurativa clinic, Albert Young, Kathy Lu, Andrea Dai, Dheeraj Kagithala, Eglal Samir, Mark Gregory, Madison Romanski, Peter Dimitrion, Iltefat Hamzavi, and Qing-Sheng Mi
Conjunctivitis adverse events in dupilumab clinical trials, Matthew Zirwas, Raj Chovatiya, Linda F. Stein Gold, Brad Shumel, Amy Praestgaard, Zhen Chen, Tayler Gonzalez, Guy Gherardi, and Emma Lawless
Submissions from 2023
HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes, Peter Dimitrion, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou, and Qing-Sheng Mi
CO125 Efficacy of Clascoterone Cream 1% for up to 12 Months in Patients ≥9 Years of Age with Acne vulgaris: Results from a Long-Term Extension Study, Lawrence F. Eichenfield, Adeaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, L. Moro, J. Han, Nicholas Squittieri, and A. Mazzetti
Efficacy and Safety of Clascoterone Cream 1% in Patients with Acne vulgaris across Subgroups Defined By Demographic Characteristics, Lawrence F. Eichenfield, Adelaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, L. Moro, J. Han, Nicholas Squittieri, and A. Mazzetti
42299 Long-term safety and efficacy of 1% clascoterone cream in patients <12 years old with acne>vulgaris, Lawrence F. Eichenfield, Adelaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, and Alessandro Mazzetti
42445 Eruptive Keratoacanthoma of Grzybowski in an African American Female, Kareem Elhage, Michael Kwa, and Henry W. Lim
Impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among patients with moderateto- severe non-nodular acne vulgaris (AV) administered sarecycline in real-world community practices across the US (PROSES Study), Richard G. Fried, Evan A. Rieder, Andrew F. Alexis, Hilary Baldwin, Emmy Graber, Julie C. Harper, Linda F. Stein Gold, Adelaide Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, and Ismail Kasujee
42099 Analysis of utilization of sun-protective behavior among national SPOT Skin Cancer® program screenees from 2018 to 2019, David Gao, Susan Swetter, Elena W. Hawryluk, Alan Geller, and Derek Beaulieu
43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations, Mahmoud Ghannoum, Ahmed Gamal, Ahmed Kadry, James Q. Del Rosso, Christopher Bunick, Linda F. Stein Gold, Leon Kircik, and Julie Harper
43390 Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants, Melinda Gooderham, Eric Simpson, Bob Geng, Linda F. Stein Gold, Andreas Wollenberg, Saleem A. Farooqui, Fan Zhang, and Claire Feeney
44222 Primary Cutaneous Adenoid Cystic Carcinoma: Report of a Rare Tumor with Review of the Literature, Meredith Hengy, Christina Artz, and Ben Friedman
44555 A National Cancer Database Analysis of Pleomorphic Dermal Sarcoma, Mustufa Jafry and Molly Powers
Evaluation of an SPF50 sunscreen containing photolyase and antioxidants for its antiphotoaging properties, Jessica Kern, Emily Wood, Rawaa Almukhtar, Kunal Angra, Michael Lipp, and Mitchel Goldman
PCR234 Impact of Draining Tunnels on Patient- and Physician-Reported Burden in Patients with Hidradenitis Suppurativa (HS), J. Kirby, Iltefat Hamzavi, A. P. Villani, R. B. Warren, A. Keal, A. C. Hernandez-Daly, R. Jha, H. Song, and A. B. Kimball
43533 Virtual dermoscopy course series in the improvement of resident education, Dayoung Ko, Christina Artz, and Laurie Kohen
Virtual dermoscopy course series in the improvement of resident education, Dayoung Ko, Christina Artz, and Laurie Kohen
42231 Trends In Price for Topical Corticosteroids from 2017-2021 and the Opportunity for Cost Savings Identifiable at the Point of Care: a Retrospective Study, Michael Kwa, Alexandra Guttentag, Lauren Chase, Jeroen van Meijgaard, and Henry W. Lim
41574 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Psoriasis Area and Severity Index Score by Body Region for the PSOARING 1 and 2 Trials, Alison M. Layton, Andrea Alexis, Hilary Baldwin, and Vincenzo Bettoli
41942 Improving Acne Care Recommendations From Personalising Acne: Consensus Of Experts (PACE), Alison M. Layton, Andrew Alexis, Hilary Baldwin, and Vincenzo Bettoli
Durability of efficacy and safety of roflumilast cream 0.3% in adults with chronic plaque psoriasis from a 52-Week, Phase 2 open-label safety trial, M. Lebwohl, Linda F. Stein Gold, M. J. Gooderham, K. A. Papp, L. K. Ferris, D. N. Adam, H. C. Hong, L. H. Kircik, M. Zirwas, P. Burnett, R. Higham, D. Krupa, and D. Berk
533 Mpox first skin lesion location: A reflection of mode of transmission?, J. E. Lubov, A. G. Strahan, S. Prasad, C. G. Casas, G. Hruza, Henry W. Lim, L. E. French, and E. Freeman
40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet's Syndrome, Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, and Andrea Flower
44180 Influence of Baseline Disease Severity Defined by Investigator's Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study, Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, and Andrea Flower
Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes: Findings From the UPLIFT Survey in the United States, Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda F. Stein Gold, Andrea Flower, Shauna Jardon, Cynthia Deignan, and Mark Lebwohl
42166 Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes: Findings From the UPLIFT Survey in the United States, Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda F. Stein Gold, Andrea Flower, Shauna Jardon, Cynthia Deignan, and Mark G. Lebwohl
40528 Administration of bortezomib in patients with refractory scleromyxedema: A case report, Austin Mueller, Michael Kwa, and Holly Kerr
43451 Identifying patient characteristics that contribute to a successful scalp cooling experience: a mixed methods study, Madison Novice, Taylor Novice, Natalie Guzman, Joshua Goyert, Thomas Hester, Melissa Dejonckheere, Justine Wu, and Jacqueline Jeruss
